argenx Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx or view top-rated stocks.

Wall Street analysts have given argenx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but argenx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

argenx is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for argenx.

argenx SE (NASDAQ:ARGX) issued its quarterly earnings data on Thursday, July, 29th. The company reported $1.98 EPS for the quarter, beating the Zacks' consensus estimate of ($3.38) by $5.36. The firm had revenue of $320.06 million for the quarter, compared to the consensus estimate of $44.46 million. argenx had a negative trailing twelve-month return on equity of 21.19% and a negative net margin of 63.22%.
View argenx's earnings history.

argenx's stock was trading at $133.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARGX shares have increased by 147.9% and is now trading at $331.67.
View which stocks have been most impacted by COVID-19.

16 Wall Street analysts have issued 1 year price targets for argenx's shares. Their forecasts range from $250.00 to $430.00. On average, they expect argenx's stock price to reach $341.92 in the next year. This suggests a possible upside of 3.1% from the stock's current price.
View analysts' price targets for argenx or view top-rated stocks among Wall Street analysts.

Some companies that are related to argenx include Biogen (BIIB), Seagen (SGEN), Bio-Techne (TECH), Novavax (NVAX), Novozymes A/S (NVZMY), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Acceleron Pharma (XLRN), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Exelixis (EXEL) and Denali Therapeutics (DNLI).
View all of ARGX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

(ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenx trades on the NASDAQ under the ticker symbol "ARGX."

argenx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.86%), FMR LLC (9.06%), Artisan Partners Limited Partnership (5.74%), Bellevue Group AG (1.89%), Avoro Capital Advisors LLC (1.84%) and Redmile Group LLC (1.54%).

ARGX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Price T Rowe Associates Inc. MD, Redmile Group LLC, Ikarian Capital LLC, Federated Hermes Inc., TimesSquare Capital Management LLC, ArrowMark Colorado Holdings LLC, and SG3 Management LLC.

ARGX stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., BlackRock Inc., Artisan Partners Limited Partnership, Clearbridge Investments LLC, Public Sector Pension Investment Board, Bamco Inc. NY, and Woodline Partners LP.

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARGX stock can currently be purchased for approximately $331.67.

argenx has a market capitalization of $17.06 billion and generates $41.60 million in revenue each year. The company earns $-604,190,000.00 in net income (profit) each year or ($13.30) on an earnings per share basis.

argenx employs 336 workers across the globe.

The official website for argenx is www.argenx.com.

argenx is headquartered at Willemstraat 5, Breda P7, 4811 AH.

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at (176) 303-0488 or via email at [email protected].